Document Detail


Long-term results in the treatment of vitiligo with oral khellin plus UVA.
MedLine Citation:
PMID:  11358729     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
This study was performed to assess the effectiveness and short-term and long-term safety of oral khellin plus UVA (KUVA) in patients with vitiligo. Twenty-eight patients (13 males and 15 females; mean age, 34 years; [age range, 15-51 years]) most with extensive generalized vitiligo of more than 6 months duration had received KUVA at sometime during a 14-year period. The response to treatment (i.e. repigmentation of depigmented areas) was rated retrospectively comparing photographs taken before and after therapy and correlation analysis revealed that it was statistically significantly linked to the number of KUVA treatments (r = 0.833, P = 0.001) and to total cumulative UVA dose (r = 0.840, P = 0.001). Of 17 patients who had continued therapy for longer than 3 months, 7 (41%) had a good response (i.e., more than 70% repigmentation of lesional skin) after a mean of 194 treatments (range, 69-386 treatments) and a mean cumulative UVA dose of 2,036 J/cm2 (range, 690-4,411 J/cm2), whereas lower response grades were observed in the patients with lower treatment numbers. The most common short-term side effect was mild nausea, occurring in 8 of 28 patients (29%), and mainly in the first week(s) of treatment. Follow-up assessment at a mean of 40 months (range, 4-110 months) after the end of KUVA therapy available in 23 of 28 patients revealed no skin cancers or actinic skin damage in any patient. These data indicate that KUVA seems to be safe as well as effective for vitiligo, provided treatment is administered long enough.
Authors:
A Hofer; H Kerl; P Wolf
Related Documents :
18613879 - Granular parakeratosis.
10816229 - Prospective study of hair reduction by diode laser (800 nm) with long-term follow-up.
11360319 - Hair reduction using a new intense pulsed light irradiator and a normal mode ruby laser.
12850799 - Treatment of telangiectasia using the multi-pass technique with the extended pulse widt...
14619359 - Skin care intervention for patients having cardiac surgery.
18445189 - Treatment of skin swellings with c1-inhibitor concentrate in patients with hereditary a...
21302399 - The results of ankle arthrodesis with screws for end stage ankle arthrosis.
83089 - Pediculosis capitis treated with quassia tincture.
15337809 - Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain assoc...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  European journal of dermatology : EJD     Volume:  11     ISSN:  1167-1122     ISO Abbreviation:  Eur J Dermatol     Publication Date:    2001 May-Jun
Date Detail:
Created Date:  2001-05-18     Completed Date:  2001-07-12     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  9206420     Medline TA:  Eur J Dermatol     Country:  France    
Other Details:
Languages:  eng     Pagination:  225-9     Citation Subset:  IM    
Affiliation:
Department of Dermatology, University of Graz, Auenbruggerplatz 8, A-8036, Graz, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Female
Humans
Khellin / adverse effects,  therapeutic use*
Male
Middle Aged
Photochemotherapy / adverse effects,  methods*,  standards
Retrospective Studies
Severity of Illness Index
Time Factors
Treatment Outcome
Ultraviolet Therapy / adverse effects,  methods*,  standards
Vitiligo / classification,  drug therapy*,  pathology,  radiotherapy*
Chemical
Reg. No./Substance:
82-02-0/Khellin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The safety of calcitriol 3 microg/g ointment. Evaluation of cutaneous contact sensitization, cumulat...
Next Document:  Bullous pemphigoid in a leg affected with hemiparesia: a possible relation of neurological diseases ...